Health ❯ Healthcare ❯ Oncology

Targeted Therapy

HER2 Mutations Everolimus KRAS Pathway DNA Damage Response ADC (Antibody-Drug Conjugate) KRAS Gene Mutations BRAF V600E Mutation Mirvetuximab Soravtansine EGFR Mutations PIK3CA Mutations Fruquintinib DLL3-Targeted Treatments KRAS Protein Zanzalintinib

New Oral Drug Nearly Doubles Survival for Treated Metastatic Pancreatic Cancer

Targeting mutant KRAS through cyclophilin A, the pill has been made available under an FDA expanded access pathway pending formal review.

Everolimus Plus Carboplatin Delays Progression in Advanced Triple-Negative Breast Cancer, Phase 2 Study Shows